Drugs / LEISH-F3
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02071758 | Apr 2014 → Dec 2015 | visceral leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT01751048 | Mar 2013 → Jan 2015 | leishmaniasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01484548 | Jan → Aug 2012 | visceral leishmaniasis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEISH-F3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01751048 ↗ |
| Modality | Protein / enzyme biologic | “recombinant two-antigen Leishmania recombinant protein LEISH-F3” NCT01484548 ↗ |
| Route | Intramuscular | “Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56.” NCT02071758 ↗ |